Search results for "MAb"

showing 10 items of 1716 documents

Osteoporosis, densidad mineral ósea y complejo CKD-MBD (II): implicaciones terapéuticas

2019

Resumen: La osteoporosis (OP) y la enfermedad renal crónica (ERC) influyen independientemente en la salud ósea. Numerosos pacientes con ERC presentan una disminución de densidad mineral ósea (DMO), un elevado riesgo de fracturas por fragilidad ósea y un incremento de su morbimortalidad. Con el envejecimiento de la población estos hechos no son dependientes solo de la «osteodistrofia renal» sino también de la OP asociada. Dado que la DMO tiene capacidad predictiva en pacientes con ERC (parte I), ahora analizaremos las implicaciones terapéuticas derivadas. Análisis post hoc de estudios aleatorizados han mostrado que fármacos como alendronato, risedronato, raloxifeno, teriparatida o denosumab …

medicine.medical_specialtyeducation.field_of_studyHyperparathyroidismbusiness.industryPopulationOsteoporosis030232 urology & nephrologyurologic and male genital diseasesmedicine.diseaselcsh:Diseases of the genitourinary system. Urologylcsh:RC870-92303 medical and health sciences0302 clinical medicineDenosumabNephrologyInternal medicinemedicineTeriparatideRaloxifeneRenal osteodystrophy030212 general & internal medicinebusinesseducationmedicine.drugKidney diseaseNefrología
researchProduct

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-labe…

2013

Summary Background Patients with advanced gastric cancer have a poor prognosis and few efficacious treatment options. We aimed to assess the addition of cetuximab to capecitabine-cisplatin chemotherapy in patients with advanced gastric or gastro-oesophageal junction cancer. Methods In our open-label, randomised phase 3 trial (EXPAND), we enrolled adults aged 18 years or older with histologically confirmed locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction. We enrolled patients at 164 sites (teaching hospitals and clinics) in 25 countries, and randomly assigned eligible participants (1:1) to receive first-line chemotherapy with …

medicine.medical_specialtyeducation.field_of_studyIntention-to-treat analysisCetuximabbusiness.industryPopulationMedizinRashSurgeryRamucirumabCapecitabineRegimenOncologyInternal medicineClinical endpointMedicinemedicine.symptombusinesseducationmedicine.drugThe Lancet Oncology
researchProduct

FRI0189 POOLED ANALYSIS OF THE REAL-WORLD EFFECTIVENESS OF BELIMUMAB IN TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS USING MULTI-COUNTRY DATA FROM THE O…

2019

Background: Real-world evidence of belimumab effectiveness in patients with systemic lupus erythematosus (SLE) has been reported separately for several countries through the OBSErve (evaluation Of use of Belimumab in clinical practice SEttings) programme. Objectives: To evaluate the effectiveness of belimumab in patients with SLE using pooled data from the individual OBSErve studies. Methods: This was a post hoc meta-analysis (GSK study 206351) of patient level data pooled from six retrospective observational cohort studies (Argentina, Canada, Germany, Spain, Switzerland, United States of America). Physicians provided data for adults (≥18 years; clinical diagnosis of SLE) who had initiated …

medicine.medical_specialtyeducation.field_of_studySystemic lupus erythematosusbusiness.industryPopulationmedicine.diseaseBelimumabPooled analysisInternal medicineSteroid sparingmedicineObservational studyeducationbusinessCohort studyMulti countrymedicine.drugPoster Presentations
researchProduct

Predicting risk of acute rejection in patients with kidney transplants

2009

Objective: Create a model to predict the risk of acute rejection of kidney transplant considering variables related to the immunosuppressant agent used, the receiver, the donor, and the transplanted organ. Methods: Cohort study in a population of 68 patients with kidney transplants being treated with tacrolimus triple therapy. Predicting the risk of acute rejection was carried out with a logistic regression analysis using age, sex, retransplant status, number of HLA incompatibilities, cold ischaemia time, acute tubular necrosis, induction with basiliximab or thymoglobulin, and treatment type as explanatory variables. The contribution of variables associated with determining the blood concen…

medicine.medical_specialtyeducation.field_of_studyThymoglobulinBasiliximabbusiness.industryPopulationmedicine.diseaseLogistic regressionGastroenterologyTacrolimusSurgeryInternal medicinemedicineeducationbusinessKidney transplantationAcute tubular necrosismedicine.drugCohort studyFarmacia Hospitalaria (English Edition)
researchProduct

Prophylaxis of Macular Edema with Intravitreal Ranibizumab in Patients with Diabetic Retinopathy after Cataract Surgery: A Pilot Study

2011

The purpose of this study was to evaluate the effectiveness of intravitreal ranibizumab (Lucentis, Genentech, South San Francisco, Calif, USA) combined with cataract surgery for the prevention of clinically significant macular edema (CSME) in patients with diabetic retinopathy (DR). This prospective interventional case series included fifty-four eyes of 54 patients with a previous diagnosis of nonproliferative diabetic retinopathy (NPDR) without macular edema preoperatively. Subjects were assigned in a 1 : 1 ratio to receive an intraoperative intravitreal ranibizumab injection (n=27) or not (control group,n=27) associated with standardised phacoemulsification surgery. The main outcome measu…

medicine.medical_specialtygenetic structuresArticle Subjectbusiness.industrymedicine.medical_treatmentIncidence (epidemiology)After cataractPhacoemulsificationDiabetic retinopathyCataract surgerymedicine.diseaseeye diseasesSurgeryOphthalmologylcsh:Ophthalmologylcsh:RE1-994OphthalmologymedicineClinical StudyIn patientIntravitreal ranibizumabbusinessMacular edemaJournal of Ophthalmology
researchProduct

Evolving European guidance on the medical management of neovascular age related macular degeneration

2006

BACKGROUND: Until recently, only two options were available for the treatment of choroidal neovascularisation (CNV) associated with age related macular degeneration (AMD)-thermal laser photocoagulation and photodynamic therapy with verteporfin (PDT-V). However, new treatments for CNV are in development, and data from phase III clinical trials of some of these pharmacological interventions are now available. In light of these new data, expert guidance is required to enable retina specialists with expertise in the management of AMD to select and use the most appropriate therapies for the treatment of neovascular AMD. METHODS: Consensus from a round table of European retina specialists was obt…

medicine.medical_specialtygenetic structuresBevacizumabAntibodies Monoclonal HumanizedTriamcinolone AcetonideMacular DegenerationCellular and Molecular NeuroscienceRanibizumabOphthalmologymedicineHumansPregnadienediolsEvidence-Based Medicinemedicine.diagnostic_testbusiness.industryAntibodies MonoclonalAptamers NucleotideMacular degenerationFluorescein angiographymedicine.diseaseVerteporfinChoroidal Neovascularizationeye diseasesSensory SystemsOphthalmologyTreatment Outcomemedicine.anatomical_structureChoroidal neovascularizationPhotochemotherapyPerspectivesense organsAnecortave acetateChoroidRanibizumabmedicine.symptombusinessmedicine.drugBritish Journal of Ophthalmology
researchProduct

Effectiveness of Rehabilitative Intervention on Pain, Postural Balance, and Quality of Life in Women with Multiple Vertebral Fragility Fractures: A P…

2021

Patients with vertebral fragility fractures often experience chronic pain, postural and balance disorders, and poor quality of life (QoL). Although several studies have investigated the role of rehabilitation in severe osteoporosis, the effectiveness of this intervention in patients with multiple vertebral fractures is poorly known. The aim of our longitudinal cohort study is to evaluate the effectiveness of rehabilitation, including postural training, resistance exercises, and visual stabilization exercises, for a 7-week period, on the pain, postural balance, and QoL of subjects with at least two vertebral fragility fractures receiving denosumab and vitamin D. We investigated, before (T0) …

medicine.medical_specialtylcsh:Diseases of the musculoskeletal systemHistologymedicine.medical_treatmentOsteoporosisvertebral fragility fractures030209 endocrinology & metabolismPhysical Therapy Sports Therapy and RehabilitationArticlerehabilitation03 medical and health sciences0302 clinical medicineRheumatologyQuality of lifePostural BalanceMedicineosteoporosiOrthopedics and Sports Medicinepain030212 general & internal medicineProspective cohort studypostural balanceRehabilitationbusiness.industrySettore MED/34 - Medicina Fisica E RiabilitativaPosturographyChronic painmedicine.diseaseosteoporosisDenosumabquality of lifePhysical therapylcsh:RC925-935Anatomybusinessvertebral fragility fracturemedicine.drugJournal of functional morphology and kinesiology
researchProduct

Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid : a systematic review and meta-ana…

2020

Background The aim of the present study was to analyse the incidence, risk ratio (RR) and prognoses of two types of medication-related osteonecrosis of the jaws (MRONJ): denosumab-related osteonecrosis of the jaws (DRONJ) and Bisphosphonate-Related Osteonecrosis of the Jaws (BRONJ) in cancer patients under treatment with denosumab or zoledronic acid (ZA). Material and Methods An electronic and manual search was conducted for randomized controlled trials (RCTs) until May 2019. Assessment of the identified studies, risk of bias and data extraction were performed independently by two reviewers. The incidence of DRONJ and BRONJ and the RR to develop MRONJ were calculated at 1 year, 2 years and …

medicine.medical_specialtymedication-related osteonecrosis of the jawsPHASE-3SKELETAL-RELATED EVENTSneoplasmsbisphosphonate-associated osteonecrosis of the JawsReviewBREASTZoledronic AcidDISEASElaw.invention03 medical and health scienceszoledronic acidDOUBLE-BLIND0302 clinical medicineRandomized controlled triallawInternal medicineNeoplasmsDentistry Oral Surgery & MedicinemedicineHumansGeneral DentistryRISKBONE METASTASESBisphosphonate-associated osteonecrosis of the jawScience & TechnologyOral Medicine and PathologyBone Density Conservation AgentsDiphosphonatesbusiness.industryIncidence (epidemiology)030206 dentistryOdds ratiomedicine.disease:CIENCIAS MÉDICAS [UNESCO]DenosumabZoledronic acidOtorhinolaryngologyMeta-analysisRelative riskUNESCO::CIENCIAS MÉDICASSurgeryBisphosphonate-Associated Osteonecrosis of the JawDenosumabbusinessLife Sciences & Biomedicinemedicine.drug
researchProduct

OP0048 Outcomes in Systemic Lupus Erythematous (SLE) Patients Treated with Belimumab in Clinical Practice Settings: Results from the Observe Study in…

2014

Background Large-scale clinical trials have demonstrated clinical efficacy of belimumab in SLE patients. Objectives This study examined the clinical outcomes associated with belimumab in clinical practice settings in Germany. Methods OBSErve (GSK 117214) is a multi-center retrospective medical chart review study. Twenty-one rheumatologists from Germany treating >10 SLE-patients annually and with at least >5 yrs of practice experience were selected for data reporting. Adult SLE patients meeting the ACR classification criteria who received belimumab (10mg/kg) as part of usual care were identified for chart abstraction. Index date was the date of belimumab initiation. The primary outcome measu…

medicine.medical_specialtymedicine.drug_classbusiness.industryMedical recordImmunologymedicine.diseaseRashBelimumabGeneral Biochemistry Genetics and Molecular BiologyDiscontinuationClinical trialRheumatologyHeart failureInternal medicinemedicinePhysical therapyImmunology and AllergyCorticosteroidmedicine.symptomAdverse effectbusinessmedicine.drugAnnals of the Rheumatic Diseases
researchProduct

Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany—Updated series of 120 cases

2020

Background Idarucizumab is a monoclonal antibody fragment with high affinity for dabigatran reversing its anticoagulant effects within minutes. Thereby, patients with acute ischemic stroke who are on dabigatran treatment may become eligible for thrombolysis with recombinant tissue-type plasminogen activator (rt-PA). In patients on dabigatran with intracerebral hemorrhage idarucizumab could prevent lesion growth. Aims To provide insights into the clinical use of idarucizumab in patients under effective dabigatran anticoagulation presenting with signs of acute ischemic stroke or intracranial hemorrhage. Methods Retrospective data collected from German neurological/neurosurgical departments ad…

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentMedizinAntibodies Monoclonal HumanizedAntithrombinsBrain IschemiaDabigatranGermanyInternal medicinemedicineHumansThrombolytic Therapyddc:610Ischemic StrokeRetrospective StudiesIntracerebral hemorrhagebusiness.industryAnticoagulantWarfarinIdarucizumabAtrial fibrillationThrombolysisVitamin K antagonistmedicine.diseaseDabigatranStrokeNeurologyCardiologybusinessIntracranial Hemorrhagesmedicine.drugInternational Journal of Stroke
researchProduct